FDA OKs Tygacil

The FDA has approved Wyeth Pharmaceuticals' antibiotic Tygacil to treat bacterial infections. The move gives hospitals another weapon in the war against new and disturbingly durable infections, including methicillin-resistant staph aureus, or MRSA, which has spread beyond hospitals and into the community. The new antibiotic is intended to combat a broad range of bacteria. Side effects include nausea and vomiting.

- read this article from the AP for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.